[CLSTR]
API
< Back to situations

[ORGANIZATION]

Eli Lilly and Company

Featured in 61 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [DK] [BR]

Novo Nordisk raises 2026 guidance amid GLP-1 growth

114 clusters · 554 sources · last updated

Latest: Novo Nordisk raises 2026 outlook as Wegovy pill sales exceed expectations

Novo Nordisk is navigating market volatility and patent risks, specifically the potential for generic competition as U.S. patents for its primary active ingredients expire in 2032. While the company faces intense competi

[ACTIVE] [BUSINESS] [US]

AbbVie financial performance and strategic transition

3 clusters · 11 sources · last updated

Latest: AbbVie raises annual outlook as Skyrizi and Rinvoq drive growth

AbbVie is undergoing a strategic shift in its pharmaceutical focus, moving from its legacy product Humira toward new immunology and oncology treatments. In fiscal year 2025, the company reported revenue of $61.2 billion,

[ACTIVE] [HEALTH] [US] [GB] [SE]

Expanding therapeutic uses and regulatory concerns for GLP-1

38 clusters · 164 sources · last updated

Latest: Semaglutide research explores broader benefits and drug metabolism effects

Medical research continues to expand the therapeutic potential of GLP-1 receptor agonists like semaglutide and tirzepatide. While semaglutide is widely used for weight loss and diabetes, new evidence suggests it may slow

[QUIET] [BUSINESS] [US]

Eli Lilly market growth and pharmaceutical expansion

6 clusters · 29 sources · last updated

Latest: Eli Lilly raises revenue guidance following strong weight loss drug sales

Eli Lilly has experienced significant financial growth and market recognition driven by its diabetes and weight-loss medication portfolio. This momentum led the company to become the first healthcare company to reach a $

[QUIET] [HEALTH] [US] [ES] [AT]

Alzheimer's research: Detection, trials, and efficacy debate

27 clusters · 97 sources · last updated

Latest: Alzheimer’s research advances with new therapies and ultrasound trials

Research into Alzheimer’s disease continues to evolve, focusing on early detection, molecular mapping, and the physiological breadth of the condition. While previous efforts emphasized biomarkers and AI-driven diagnostic

[QUIET] [HEALTH] [US]

US psychedelic therapy regulatory and research developments

6 clusters · 13 sources · last updated

Latest: U.S. Federal Officials Outline Roadmap for Psychedelic Medicine Approval

The U.S. Food and Drug Administration (FDA) is developing a framework to accelerate access to psychedelic medicines, such as psilocybin and DMT, to address the national mental health crisis. Recent FDA public hearings ha

[QUIET] [HEALTH] [BR] [PY] [FR]

Brazil ANVISA expands product safety enforcement

43 clusters · 290 sources · last updated

Latest: Anvisa bans Accu-Chek Active glucose test strips on Amazon

Since May 2026, Brazil’s National Health Surveillance Agency (ANVISA) has intensified enforcement of sanitary rules for pharmaceuticals, cosmetics, and consumer goods. Early actions included suspending batches of statins

[QUIET] [HEALTH] [IT] [AU] [US]

Evolution of obesity medication treatments

3 clusters · 9 sources · last updated

Latest: Obesity research advances toward oral treatments

The landscape of obesity treatments is shifting toward more convenient delivery methods, specifically weekly injections and oral therapies. In the United States, Viking Therapeutics is preparing to begin phase 3 clinical

[QUIET] [HEALTH] [RO]

Public health trends in Romania

2 clusters · 12 sources · last updated

Latest: Cardiovascular disease rising among younger populations in Romania

Medical professionals in Romania are reporting concerning trends regarding the prevalence of chronic health conditions. In September 2026, health authorities highlighted a rise in Alzheimer’s disease cases. The Nationa

[QUIET] [HEALTH] [US] [DE] [GB]

Eli Lilly retatrutide development and black market issues

11 clusters · 32 sources · last updated

Latest: Incretin agonists show potential in obesity treatment amid safety concerns

In early August 2026, Eli Lilly announced that its experimental obesity treatment retatrutide achieved substantial weight-loss outcomes in two phase-3 trials. Participants lost up to 22.6% of body weight over 80 weeks in

[QUIET] [HEALTH] [US] [AU] [GB]

Advancements in Alzheimer's detection, AI, and drug access

18 clusters · 83 sources · last updated

Latest: Dementia diagnosis and new drugs improve patient outlook

Research into Alzheimer's biomarkers continues to evolve, with recent findings refining the utility of blood-based testing. While plasma p-tau217 remains a key indicator, studies suggest its predictive power in symptom-f

Also covered in